DATASPARK/OOREDOO
29.6.2021 02:02:07 CEST | Business Wire | Press release
DataSpark has signed a multi-year strategic deal with communications giant, Ooredoo Group, to automate and standardise their group-wide network planning processes, optimise capital expenditure spending and deliver superior customer experience.
The agreement will see DataSpark introduce its state-of-the-art Smart Network Planning (SNP) product to help establish an advanced analytics platform and capability in network planning across all 10 Ooredoo Group operating companies around the world.
The SNP solution (also referred to as CAPEX Optimizer in some regions) will deliver cost and operational efficiencies for Ooredoo Group’s network expansion investments while ensuring that fast-evolving customer needs are always kept at the centre of decision making.
The product utilises advanced machine learning methodologies to forecast and anticipate network capacity and throughput ahead of time, enabling Ooredoo to direct its capital expenditure in a way that creates the most value for the end customer.
DataSpark Chief Operating Officer, Shaowei Ying, said the partnership is a testament to DataSpark’s ability to provide performance-driven analytics solutions for global telco providers.
“The SNP solution empowers Ooredoo’s operating companies to have an automated, data-driven and customer-centric approach to their radio network capacity planning. It leverages best-in-class technologies that DataSpark developed over the last decade to process data at scale and extract granular insights for decision optimisation,” said Mr Ying. “We welcome this landmark partnership with Ooredoo Group which represents a significant milestone. DataSpark, as part of NCS NEXT, will continue expanding telco-centric analytic solutions and collaborate with telecommunication clients globally.”
The SNP’s application for telcos is founded on several key factors including automated and cost-efficient network planning through customer experience, services and network metrics, and layered analytics to inform accurate network investment decisions.
Ooredoo Group Chief Technology and Information Officer, Nigel Thomas Byrne, said the company’s venture with DataSpark would help ensure visibility and standardisation into network planning activities across the Ooredoo Group. This will also help in sharing network planning best practices across the group and further strengthen the culture of data-driven decision making.
“The insights and recommendations delivered through DataSpark’s SNP solution will provide cost-optimisation and allow us to innovate with our networks, ultimately enhancing the customer experience,” said Mr Byrne. “Our mission to deliver superior service is predicated on high-performance network planning and capacity management, and SNP’s advanced analytics will help us make informed decisions to deliver on this goal.”
DataSpark’s mobility data products are designed to optimise telco network solutions for revenue growth and improve customer satisfaction. DataSpark empowers organisations with mobility intelligence to help maximise the value of their networks and save on capital investment spending. Existing telecommunication clients include Singtel, Optus, Advanced Info Service and Globe Telecom.
About DataSpark: DataSpark are leaders in processing large geospatial temporal mobility data to deliver intelligence on people and places using the highest data privacy standards. Understanding how people move, where they go and what they do enables organisations to make more informed decisions from planning capital expenditure to creating better customer experiences. DataSpark (known as DSpark in Australia) is part of the NCS Group with offices across Australia, Singapore, the Philippines, and Indonesia. For more information, visit dsanalytics.com .
About NCS: NCS is a member of the Singtel Group and the leading information, communications and technology (ICT) service provider with presence in the Asia Pacific region. NCS delivers end-to-end ICT and digital solutions to help governments and enterprises realise business value through digital transformation and the innovative use of technology. NCS invests in NEXT capabilities of digital, cloud, platform and cyber while continuously strengthening its core offerings of applications, infrastructure and engineering. For more information, visit ncs.com.sg .
About Ooredoo: Ooredoo is a leading international communications company delivering mobile, fixed, broadband internet and corporate managed services tailored to the needs of consumers and businesses across markets in the Middle East, North Africa and Southeast Asia. For more information, visit ooredoo.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
